Source link : https://newshealth.biz/health-news/co-antibody-therapy-effective-in-highly-refractory-ibd/
The co-antibody therapy JNJ-4804 — a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) — showed clinically meaningful efficacy exceeding that of either drug alone in patients with highly refractory inflammatory bowel disease (IBD), according to two phase IIb trials. Meanwhile, in the overall study population, the efficacy of high-dose JNJ-4804 was superior to golimumab […]
The post Co-Antibody Therapy Effective in Highly Refractory IBD first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-08 20:04:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8